Conference Call with Marksans Pharma Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Marksans Pharma announced Q2FY26 results Q2FY26 Financial Highlights: Operating revenue stood at Rs 720.4 crore, up by 12.2% YoY, attributed to strong traction in the US market, supported by new product launches across the digestive and pain management segments. Gross profit stood at Rs 411.8 crore, up by 7.4% YoY, with gross margin of 57.2%. EBITDA stood at Rs 144.5 crore., with a margin of 20.1%. EPS was at Rs 2.2. Other Highlights: Cash generated from operations at Rs 75.2 crore during H1FY26. Capex of Rs 73.2 crore incurred during H1FY26. Working capital cycle ~150 days for Q2FY26. Cash balance of Rs 666.5 crore as on 30th September 2025. Research & development (R&D;) spends at Rs 26.2 crore in H1FY26, 2.0% of consolidated revenue Mark Saldanha, Managing Director, said: “Q2FY26 has been a strong quarter for us, with revenues growing 16% sequentially, driven by robust demand across our key markets. The US region recorded solid growth, demonstrating resilience amid macro challenges, supported by stabilizing tariff conditions, timely order book execution, and meaningful traction from new product launches. The UK market also witnessed improved demand and delivered stable results despite continued pricing pressures. Our EBITDA and PAT grew 44% and 70% QoQ, reflecting the benefits of operating leverage. Looking ahead, we remain optimistic about sustaining this momentum into the second half of the year. Our strategic focus and operational discipline position us well to deliver resilient growth and long-term value for our stakeholders.” Result PDF
